Drugs for bad bugs: confronting the challenges of antibacterial discovery

By D. Payne, M. Gwynn, D. Holmes, D. Pompliano. Nature reviews. Drug discovery, 2007

2,400 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Molecular Medicine, Pharmacology

View Paper: https://www.semanticscholar.org/paper/5d177379a4442139cadd50610985f4a993cbb936

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

1. Robert E. W. Hancock
2. D. Newman
3. Kim Lewis
4. A. Hopkins
5. G. Cragg
6. Gisbert Schneider

In Molecular Medicine

1. Annelies S. Zinkernagel
2. M. Huemer
3. S. Brugger
4. Srikanth Mairpady Shambat
5. Stefan H. E. Kaufmann
6. M. Gengenbacher
7. Robert E. W. Hancock
8. Leonard Katz

In Pharmacology

1. G. Cragg
2. D. Newman
3. Leonard Katz
4. R. H. Baltz
5. M. Huemer
6. Robert E. W. Hancock
7. S. Brugger
8. Kim Lewis

Citations in the corpus

• Targeting virulence: a new paradigm for antimicrobial therapy (2007, background): “GlaxoSmithKline recently undertook a genomic, target and whole cell–based approach over a period of seven years to identify compounds that inhibit genes thought to be essential for viability in a number of pathogen”
• Predictive compound accumulation rules yield a broad-spectrum antibiotic (2017, background): “5: (1) ATCC 29213; (2) NRS3; (3) MG1655, (4) ELZ4017; (5) ELZ4045; (6) ELZ4346; (7) ELZ4081; (8) ELZ4072; (9) ELZ4239; (10) BAA-2469; (11) ATCC 19606; (12) KB304; (13) KB349; (14) WO22; (15) BD335; (16) IF101; (17) ATCC 27736; (18) 4-38; (19) 6-73; (20) ATCC 29893; (21) 1-60; (22) 3-46; (23) PAO1.”
• Mycobacterium tuberculosis: Success through dormancy (2012, background): “…was expected from whole genome sequencing of Mtb and application of high-throughput screening to target-based approaches has not paid off so far, nine TB drug candidates are currently undergoing clinical investigation – more than ever before (Cole et al., 1998; Payne et al., 2007; Ma et al., 2010).”
• Use of Ichip for High-Throughput In Situ Cultivation of “Uncultivable” Microbial Species (2010, background): “With such a discovery being seemingly impractical, microbial exploration has refocused on metagenomics and high-throughput screening of synthetic compound libraries (9, 22).”
• Complement evasion by human pathogens (2008, background): “In the past, drug-screening initiatives focused mainly on bacterial metabolism targets rather than immune evasio”
• Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections (2010, background): “Antimicrobial peptides made by the host and several bioactive molecules that act on the membran”